What Is Medicine Menopause and Why It Matters Financially
Medicine menopause refers to the medical management of menopausal symptoms using hormone therapy, nonhormonal prescriptions, and digital health tools. In the United States, an estimated 6,000 women enter menopause daily, and the global menopause market is projected to exceed $20 billion by 2030. For investors and consumers, understanding the cost, access, and innovation around menopause medicine is critical because it intersects with healthcare spending, employer benefits, and pharmaceutical valuations.
Key drivers include an aging population, increased openness about menopause, and new drug approvals. Major pharmaceutical companies such as Pfizer and Astellas have invested in menopause-specific research, while startups like Evernow and Alloy Health have raised significant venture capital to offer telemedicine menopause care. The shift from general gynecology to dedicated menopause medicine is creating new revenue streams and expanding employer health plan considerations.
Latest FDA Approvals and Treatment Options in Medicine Menopause
In 2023, the FDA approved Veozah (fezolinetant), the first nonhormonal prescription treatment for moderate to severe vasomotor symptoms caused by menopause. This approval gave women a new option without the risks associated with traditional hormone therapy. Veozah is marketed by Astellas Pharma and represents a significant expansion of the medicine menopause toolkit, targeting hot flashes and night sweats with a nonhormonal mechanism.
Traditional hormone therapy remains a standard for many, with combined estrogen-progestin products from companies like Pfizer and AbbVie continuing to be widely prescribed. Bioidentical hormones and compounded formulations are also common, though the FDA has issued warnings about the risks of unregulated compounded drugs. For patients, the choice between hormone and nonhormone options often depends on medical history, cost, and access, which are increasingly influenced by insurance coverage and digital health platforms.
Costs, Market Leaders, and Investment in Medicine Menopause
The average annual out-of-pocket cost for menopause treatments in the U.S. ranges from $500 to $2,500, depending on the therapy and insurance coverage. Prescription medications, including Veozah, can cost several hundred dollars per month without insurance, though manufacturer coupons and pharmacy discount programs can reduce this. Employer-sponsored health plans are increasingly covering menopause care, including prescription drugs and telehealth visits, as part of broader women's health benefits.
Investment in the medicine menopause space has accelerated, with companies like Evernow raising over $100 million in venture funding to scale its telemedicine platform. Other notable players include Alloy Health, which focuses on personalized menopause care, and TherapeuticsMD, which develops prescription treatments for menopause symptoms. The competitive landscape is also drawing attention from traditional pharmaceutical giants, as the market for menopause therapies continues to grow and attract new entrants seeking a share of this expanding segment.